Prostaglandin EP2 and EP4 receptor agonists in bone formation and bone healing: In vivo and in vitro evidence

Expert Opinion on Investigational Drugs

Volumn 18, Issue 6, 2009, Pages 749-766

  Graham, Simon ^a   Gamie, Zakareya ^a   Polyzois, Ioannis ^a   Narvani, Amir Ali ^a   Tzafetta, Kallirroi ^a   Tsiridis, Evgenios ^b   Helioti, Manolis ^c   Mantalaris, Athanasios ^d   Tsiridis, Eleftherios ^a  

^a LEEDS GENERAL INFIRMARY   (United Kingdom)

^b Blue Cross Hospital   (Greece)

^c NORTHWICK PARK HOSPITAL   (United Kingdom)

^d IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Bone formation; Fracture; Fracture healing; Prostaglandin; Prostaglandin receptors

Indexed keywords

7 [3 HYDROXY 2 [3 HYDROXY 4 (3 METHOXYMETHYLPHENYL) 1 BUTENYL] 5 OXOCYCLOPENTYL] 5 THIAHEPTANOIC ACID METHYL ESTER; [3 [[(4 TERT BUTYLBENZYL)(3 PYRIDINESULFONYL)AMINO]METHYL]PHENOXY]ACETIC ACID; AE 604; ARACHIDONIC ACID; BUTAPROST; CP 432; CP 734432; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; L 161982; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; ONO AE 248; ONO AE1 259 01; ONO AE1 329; ONO AE2 248; ONO AE2 724; ONO D1 004; PHOSPHOLIPASE C; PROSTACYCLIN; PROSTAGLANDIN D2; PROSTAGLANDIN E RECEPTOR; PROSTAGLANDIN E2; PROSTAGLANDIN F2; PROSTAGLANDIN RECEPTOR BLOCKING AGENT; PROSTAGLANDIN RECEPTOR STIMULATING AGENT; THROMBOXANE; UNCLASSIFIED DRUG; PROSTAGLANDIN; PROSTAGLANDIN E2 RECEPTOR, EP4 SUBTYPE; PROSTAGLANDIN EP2 RECEPTOR;

BONE DENSITY; BONE METABOLISM; BONE MINERAL; CELL ACTIVATION; DRUG MEGADOSE; EMBASE; FRACTURE HEALING; HUMAN; LOW DRUG DOSE; MEDLINE; NONHUMAN; OSSIFICATION; OSTEOBLAST; OSTEOLYSIS; PROSTAGLANDIN METABOLISM; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; BIOLOGICAL MODEL; BONE; BONE DEVELOPMENT; DRUG EFFECT; DRUG POTENTIATION; METABOLISM; PHYSIOLOGY;

ANIMALS; BONE AND BONES; BONE DENSITY; BONE RESORPTION; FRACTURE HEALING; HUMANS; MODELS, BIOLOGICAL; OSTEOGENESIS; PROSTAGLANDINS; RECEPTORS, PROSTAGLANDIN E;

EID: 67649616236     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543780902893051     Document Type: Review

References (64)

1. Narumiya S, Sugimoto Y, Ushikubi F. Prostanoid receptors: structures, properties, and functions. Physiol Rev 1999;79(4):1193-1226 (Pubitemid 29473315)
2. Wilson RJ, Rhodes SA, Wood RL, et al. Functional pharmacology of human prostanoid EP2 and EP4 receptors. Eur J Pharmacol 2004;501(1-3):49-58 (Pubitemid 39298936)
3. Namkoong S, Lee SJ, Kim CK, et al. Prostaglandin E2 stimulates angiogenesis by activating the nitric oxide/cGMP pathway in human umbilical vein endothelial cells. Exp Mol Med 2005;37(6):588-600
4. Axelrad TW, Kakar S, Einhorn TA. New technologies for the enhancement of skeletal repair. Injury 2007;38(Suppl 1):S49-62 (Pubitemid 46440930)
5. Singh GK, Fong LV, Salmon AP, Keeton BR. Study of low dosage prostaglandin: usages and complications. Eur Heart J 1994;15(3):377-381 (Pubitemid 24127382)
6. Cattral MS, Altraif I, Greig PD, et al. Toxic effects of intravenous and oral prostaglandin E therapy in patients with liver disease. Am J Med 1994;97(4):369-373 (Pubitemid 24313098)
7. Khan MH, Li Z, Wang JH. Repeated exposure of tendon to prostaglandin-E2 leads to localized tendon degeneration. Clin J Sport Med 2005;15(1):27-33 (Pubitemid 40283817)
8. Voegeli TL, Chapman MW. Utilization of prostaglandin in fracture healing [abstract]. Trans Orthop Res Soc 1985;10:134
9. Doggrell SA. Misoprostol for the treatment of early pregnancy failure. Curr Clin Pharmacol 2007;2(1):1-9 (Pubitemid 46729080)
10. Stadler TC, Becker AJ, Stief CG. [Modern treatment of erectile dysfunction]. MMW Fortschr Med 2008;150(15):41-43
11. Hartke JR, Lundy MW. Bone anabolic therapy with selective prostaglandin analogs. J Musculoskelet Neuronal Interact 2001;2(1):25-31
12. Kawaguchi H, Pilbeam CC, Harrison JR, Raisz LG. The role of prostaglandins in the regulation of bone metabolism. Clin Orthop Relat Res 1995;(313):36-46
13. Li M, Thompson DD, Paralkar VM. Prostaglandin E(2) receptors in bone formation. Int Orthop 2007;31(6):767-772
14. Ke HZ, Shen VW, Qi H, et al. Prostaglandin E2 increases bone strength in intact rats and in ovariectomized rats with established osteopenia. Bone 1998;23(3):249-255
15. Li XJ, Jee WS, Li YL, Patterson-buckendahl P. Transient effects of subcutaneously administered prostaglandin E2 on cancellous and cortical bone in young adult dogs. Bone 1990;11(5):353-364 (Pubitemid 20326830)
16. Dekel S, Lenthall G, Francis MJ. Release of prostaglandins from bone and muscle after tibial fracture. An experimental study in rabbits. J Bone Joint Surg Br 1981;63-B(2):185-189 (Pubitemid 11098763)
17. Keller J, Bunger C, Andreassen TT, et al. Bone repair inhibited by indomethacin. Effects on bone metabolism and strength of rabbit osteotomies. Acta Orthop Scand 1987;58(4):379-383
18. Suzawa T, Miyaura C, Inada M, et al. The role of prostaglandin E receptor subtypes (EP1, EP2, EP3, and EP4) in bone resorption: an analysis using specific agonists for the respective EPs. Endocrinology 2000;141(4):1554-1559
19. Breyer RM, Bagdassarian CK, Myers SA, Breyer MD. Prostanoid receptors: subtypes and signaling. Annu Rev Pharmacol Toxicol 2001;41:661-690 (Pubitemid 32385902)
20. Hakeda Y, Yoshino T, Natakani Y, et al. Prostaglandin E2 stimulates DNA synthesis by a cyclic AMP-independent pathway in osteoblastic clone MC3T3-E1 cells. J Cell Physiol 1986;128(2):155-161 (Pubitemid 16047923)
21. Chase LR, Aurbach GD. The effect of parathyroid hormone on the concentration of adenosine 3′,5′-monophosphate in skeletal tissue in vitro. J Biol Chem 1970;245(7):1520-1526
22. Yu JH, Wells H, Ryan WJ, Lloyd WS. Effects of prostaglandins and other drugs on the cyclic AMP content of cultured bone cells. Prostaglandins 1976;12(4):501-513
23. Marcus R, Orner FB. Cyclic AMP production in rat calvaria in vitro: interaction prostaglandins with parathyroid hormone. Endocrinology 1977;101(5):1570-1578 (Pubitemid 8223377)
24. Alander CB, Raisz LG. Effects of selective prostaglandins E2 receptor agonists on cultured calvarial murine osteoblastic cells. Prostaglandins Other Lipid Mediat 2006;81(3-4):178-183 (Pubitemid 44666501)
25. Suda M, Tanaka K, Natsui K, et al. Prostaglandin E receptor subtypes in mouse osteoblastic cell line. Endocrinology 1996;137(5):1698-1705 • One of the first studies to demonstrate the presence of PGE receptors in the bone of mice and rats.
26. Weinreb M, Machwate M, Shir N, et al. Expression of the prostaglandin E(2) (PGE(2)) receptor subtype EP(4) and its regulation by PGE(2) in osteoblastic cell lines and adult rat bone tissue. Bone 2001;28(3):275-281
27. Weinreb M, Grosskopf A, Shir N. The anabolic effect of PGE2 in rat bone marrow cultures is mediated via the EP4 receptor subtype. Am J Physiol 1999;276(2 Pt 1):E376-83 (Pubitemid 29100595)
28. Sarrazin P, Bkaily G, Hache R, et al. Characterization of the prostaglandin receptors in human osteoblasts in culture. Prostaglandins Leukot Essent Fatty Acids 2001;64(3):203-210
29. Billot X, Chateauneuf A, Chauret N, et al. Discovery of a potent and selective agonist of the prostaglandin EP4 receptor. Bioorg Med Chem Lett 2003;13(6):1129-1132
30. Maruyama T, Asada M, Shiraishi T, et al. Design and synthesis of a selective EP4-receptor agonist. Part 3: 16-phenyl-5-thiaPGE(1) and 9-beta-halo derivatives with improved stability. Bioorg Med Chem 2002;10(6):1743-1759
31. Shamir D, Keila S, Weinreb M. A selective EP4 receptor antagonist abrogates the stimulation of osteoblast recruitment from bone marrow stromal cells by prostaglandin E2 in vivo and in vitro. Bone 2004;34(1):157-162 (Pubitemid 38142444)
32. Sakuma Y, Li Z, Pilbeam CC, et al. Stimulation of cAMP production and cyclooxygenase-2 by prostaglandin E(2) and selective prostaglandin receptor agonists in murine osteoblastic cells. Bone 2004;34(5):827-834
33. Faour WH, He Y, He QW, et al. Prostaglandin E(2) regulates the level and stability of cyclooxygenase-2 mRNA through activation of p38 mitogen-activated protein kinase in interleukin-1 beta-treated human synovial fibroblasts. J Biol Chem 2001;276(34):31720-31731
34. Hinz B, Brune K, Pahl A. Cyclooxygenase-2 expression in lipopolysaccharide-stimulated human monocytes is modulated by cyclic AMP, prostaglandin E(2), and nonsteroidal anti-inflammatory drugs. Biochem Biophys Res Commun 2000;278(3):790-796
35. Mano M, Arakawa T, Mano H, et al. Prostaglandin E2 directly inhibits bone-resorbing activity of isolated mature osteoclasts mainly through the EP4 receptor. Calcif Tissue Int 2000;67(1):85-92 •• The first study to report the presence of EP4 receptors on mature osteoclasts.
36. Okada Y, Lorenzo JA, Freeman AM, et al. Prostaglandin G/H synthase-2 is required for maximal formation of osteoclast-like cells in culture. J Clin Invest 2000;105(6):823-32 37. Kaji H, Sugimoto T, Kanatani M, et al. Prostaglandin E2 stimulates osteoclast-like cell formation and bone-resorbing activity via osteoblasts: role of cAMP-dependent protein kinase. J Bone Miner Res 1996;11(1):62-71 (Pubitemid 30164121)
37. Zhan P, Alander C, Kaneko H, et al. Effect of deletion of the prostaglandin EP4 receptor on stimulation of calcium release from cultured mouse calvariae: impaired responsiveness in heterozygotes. Prostaglandins Other Lipid Mediat 2005;78(1-4):19-26
38. Raisz LG, Woodiel FN. Effects of selective prostaglandin EP2 and EP4 receptor agonists on bone resorption and formation in fetal rat organ cultures. Prostaglandins Other Lipid Mediat 2003;71(3-4):287-292 (Pubitemid 36929797)
39. Ono K, Akatsu T, Murakami T, et al. Important role of EP4, a subtype of prostaglandin (PG) E receptor, in osteoclast-like cell formation from mouse bone marrow cells induced by PGE2. J Endocrinol 1998;158(3):R1-5 (Pubitemid 28407553)
40. Sakuma Y, Tanaka K, Suda M, et al. Crucial involvement of the EP4 subtype of prostaglandin E receptor in osteoclast formation by proinflammatory cytokines and lipopolysaccharide. J Bone Miner Res 2000;15(2):218-227 (Pubitemid 30095708)
41. Li X, Okada Y, Pilbeam CC, et al. Knockout of the murine prostaglandin EP2 receptor impairs osteoclastogenesis in vitro. Endocrinology 2000;141(6):2054-2061
42. Yoshida K, Oida H, Kobayashi T, et al. Stimulation of bone formation and prevention of bone loss by prostaglandin E EP4 receptor activation. Proc Natl Acad Sci U S A 2002;99(7):4580-4585
43. Ke HZ, Crawford DT, Qi H, et al. A nonprostanoid EP4 receptor selective prostaglandin E2 agonist restores bone mass and strength in aged, ovariectomized rats. J Bone Miner Res 2006;21(4):565-575
44. Machwate M, Harada S, Leu CT, et al. Prostaglandin receptor EP(4) mediates the bone anabolic effects of PGE(2). Mol Pharmacol 2001;60(1):36-41
45. Hagino H, Kuraoka M, Kameyama Y, et al. Effect of a selective agonist for prostaglandin E receptor subtype EP4 (ONO-4819) on the cortical bone response to mechanical loading. Bone 2005;36(3):444-453
46. Turner CH, Akhter MP, Raab DM, et al. A noninvasive, in vivo model for studying strain adaptive bone modeling. Bone 1991;12(2):73-79
47. Torrance AG, Mosley JR, Suswillo RF, Lanyon LE. Noninvasive loading of the rat ulna in vivo induces a strain-related modeling response uncomplicated by trauma or periostal pressure. Calcified Tissue Int 1994;54(3):241-247 (Pubitemid 24076582)
48. Onishi E, Fujibayashi S, Takemoto M, et al. Enhancement of bone-bonding ability of bioactive titanium by prostaglandin E2 receptor selective agonist. Biomaterials 2008;29(7):877-883 •• This study concluded that systemic administration of EP4 agonist enhanced bone formation around bioactive titanium in rabbit models, which was related to the high titanium-bone bonding strength formed during the early stages - suggesting that EP4 agonist may have the potential to promote early bone apposition around the surface of bioactive implants in cementless joint arthroplasty.
49. Marui A, Hirose K, Maruyama T, et al. Prostaglandin E2 EP4 receptor-selective agonist facilitates sternal healing after harvesting bilateral internal thoracic arteries in diabetic rats. J Thorac Cardiovasc Surg 2006;131(3):587-593 •• Concluded that PGE2 EP4 agonist accelerated the sternal healing and decreased the incidence of sternal wound complications in diabetic rats following sternotomy. (Pubitemid 43312884)
50. Tanaka M, Sakai A, Uchida S, et al. Prostaglandin E2 receptor (EP4) selective agonist (ONO-4819.CD) accelerates bone repair of femoral cortex after drill-hole injury associated with local upregulation of bone turnover in mature rats. Bone 2004;34(6):940-948
51. Zhang X, Schwarz EM, Young DA, et al. Cyclooxygenase-2 regulates mesenchymal cell differentiation into the osteoblast lineage and is critically involved in bone repair. J Clin Invest 2002;109(11):1405-1415 (Pubitemid 34596166)
52. Naik AA, Xie C, Zuscik MJ, et al. Reduced COX-2 Expression in Aged Mice Is Associated With Impaired Fracture Healing. J Bone Miner Res 2009;24(2):251-264
53. Li M, Ke HZ, Qi H, et al. A novel, non-prostanoid EP2 receptor-selective prostaglandin E2 agonist stimulates local bone formation and enhances fracture healing. J Bone Miner Res 2003;18(11):2033-2042 • Study indicated the EP2 agonist CP-533,536 can augment bone formation and enhance fracture repair, and has a promising therapeutic potential. (Pubitemid 37377454)
54. Choudhary S, Alander C, Zhan P, et al. Effect of deletion of the prostaglandin EP2 receptor on the anabolic response to prostaglandin E2 and a selective EP2 receptor agonist. Prostaglandins Other Lipid Mediat 2008;86(1-4):35-40
55. Ono K, Kaneko H, Choudhary S, et al. Biphasic effect of prostaglandin E2 on osteoclast formation in spleen cell cultures: role of the EP2 receptor. J Bone Miner Res 2005;20(1):23-29 (Pubitemid 41716215)
56. Akhter MP, Cullen DM, Gong G, Recker RR. Bone biomechanical properties in prostaglandin EP1 and EP2 knockout mice. Bone 2001;29(2):121-125
57. Suda T, Udagawa N, Nakamura I, et al. Modulation of osteoclast differentiation by local factors. Bone 1995;17(2 Suppl):87S-91S
58. Quinn JM, Elliott J, Gillespie MT, Martin TJ. A combination of osteoclast differentiation factor and macrophage-colony stimulating factor is sufficient for both human and mouse osteoclast formation in vitro. Endocrinology 1998;139(10):4424-4427 (Pubitemid 28513734)
59. Li X, Pilbeam CC, Pan L, et al. Effects of prostaglandin E2 on gene expression in primary osteoblastic cells from prostaglandin receptor knockout mice. Bone 2002;30(4):567-573
60. Paralkar VM, Borovecki F, Ke HZ, et al. An EP2 receptor-selective prostaglandin E2 agonist induces bone healing. Proc Natl Acad Sci USA 2003;100(11):6736-6740
61. Nemoto K, Pilbeam CC, Bilak SR, Raisz LG. Molecular cloning and expression of a rat prostaglandin E2 receptor of the EP2 subtype. Prostaglandins 1997;54(4):713-725 (Pubitemid 28020936)
62. Kasugai S, Oida S, Iimura T, et al. Expression of prostaglandin E receptor subtypes in bone: expression of EP2 in bone development. Bone 1995;17(1):1-4
63. Boie Y, Stocco R, Sawyer N, et al. Molecular cloning and characterization of the four rat prostaglandin E2 prostanoid receptor subtypes. Eur J Pharmacol 1997;340(2-3):227-241 (Pubitemid 28022647)
64. Nakagawa K, Imai Y, Ohta Y, Takaoka K. Prostaglandin E2 EP4 agonist (ONO-4819) accelerates BMP-induced osteoblastic differentiation. Bone 2007;41(4):543-548 (Pubitemid 47385438)